Tabletop Patient Monitor

If it were possible to identify high-risk patients at the onset of their cardiovascular disease, would you modify your treatment approach?

The EndoPAT test from Itamar Medical is the sole FDA-cleared test for the non-invasive assessment of endothelial dysfunction (arterial health). It has been clinically proven to be a valuable tool in cardiovascular risk stratification beyond commonly used tests by leading cardiologists in prestigious peer-reviewed studies.

The cardiovascular system and autonomic nervous system can be observed through PAT®️ technology, which is non-invasive. The Peripheral Arterial Tone (PAT®️) signal is a proprietary technology that is employed to non-invasively measure changes in arterial tone in peripheral arterial beds.

The cardiovascular system and autonomic nervous system can be observed through PAT®️ technology, which is non-invasive. The Peripheral Arterial Tone (PAT®️) signal is a proprietary technology that is employed to non-invasively measure changes in arterial tone in peripheral arterial beds.input:
output:The PAT®️ bio-sensors are distinguished by their ability to deliver a consistent sub-diastolic pressure field to the distal two-thirds of the fingers, including their tips.input:
output:Endothelial dysfunction

The medical community has acknowledged endothelial dysfunction as the critical interface between cardiovascular disease risk factors and clinical disease for more than a decade. It is the earliest stage of cardiovascular disease that can be detected. Additionally, it is treatable and, in contrast to the atherosclerotic plaque it induces, it is even reversible.